arrow
V

Vincent T. Ho

Dana-Farber Cancer Institute
H指数:86
被引数:2.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Reactogenicity and Immunogenicity of RSV Vaccines in Immunocompromised Individuals With Hematological Malignancies

造血系统恶性肿瘤免疫受损个体中RSV疫苗的反应原性和免疫原性

2026-09-200
OAAI
Venetoclax-augmented RIC allogeneic HCT with PTCy-based GVHD prophylaxis and venetoclax/azacitidine maintenance for poor risk MDS and AML

维奈克拉增强的RIC同种异基因HCT联合PTCy为基础的GVHD预防及维奈克拉/阿扎胞苷维持治疗高危MDS和AML

2026-08-190
OAAI
Effects of post-transplant cyclophosphamide on immune reconstitution after haploidentical and HLA-matched transplant

异基因和HLA匹配移植后环磷酰胺对免疫重建的影响

2026-01-010
OAAI
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse

自造血干细胞移植(HCT)后复发急性髓系白血病(AML)并达到缓解的患者,细胞疗法巩固治疗并无明确益处。

2025-11-040
OAAI
Hematopoietic Cell Transplantation, Version 3.2025

造血细胞移植,版本 3.2025

2025-10-011
PRE
Expression of HLA-B*35 is Associated with an Increased Risk of CMV Viremia and Clinically Significant CMV Infection following PTCy-based Hematopoietic Cell Transplantation

HLA-B*35的表达与PTCy-based造血细胞移植后巨细胞病毒(CMV)病毒血症及临床显著CMV感染风险的增加相关。

2025-09-210
PRE
An ASTCT, CIBMTR, EBMT, and APBMT Consensus Statement Defining Response Criteria for Hematopoietic Cell Transplantation Associated Thrombotic Microangiopathy (TA-TMA) Directed Therapy

ASTCT、CIBMTR、EBMT和APBMT关于造血细胞移植相关血栓性微血管病(TA-TMA)导向治疗反应标准的共识声明

2025-06-010
OAAI
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML
2024-02-165
OAAI
Clinical Features of Acute Kidney Injury in the Early Post-Transplantation Period Following Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation

低强度预处理异基因造血干细胞移植后早期急性肾损伤的临床特征

2023-07-014
OAAI
Single-cell landscape analysis unravels molecular programming of the human B cell in chronic GVHD
2023-06-085
OA